- Published: Monday, 14 October 2013 16:24
AstraZeneca is a global, innovation-driven biopharmaceutical business.
We focus on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
We continue to partner with others to access the best science and accelerate the development of new medicines in both small molecules and biologics. We are active in building early stage biotech and academic alliances alongside in-licensing and acquisitions to strengthen our pipeline and broaden the range of treatment options for physicians and patients.
Our business environment continues to present both opportunity and challenge. There is a growing demand for healthcare worldwide, driven by increasing and ageing patient populations and fast-emerging new markets. There are still many diseases for which treatments are inadequate or effective therapies do not exist.
Our strategy sets out our path for managing the challenges and leveraging the opportunities of a dynamic business environment. It is founded on three core priorities:
Achieve scientific leadership – delivering the full potential of our unique combination of discovery and development strengths in small molecules and biologics, immunotherapies and protein engineering technologies. This includes progressing our Phase II pipeline (which has the potential to double our Phase III pipeline by 2016), and launching a steady flow of specialty care products, balancing our historic strength in primary care.
Return to growth – focusing our commercial expertise on key disease areas and high potential markets. Specifically, we are putting our weight behind five growth platforms: Brilinta (ticagrelor) - our treatment for acute coronary syndrome, our diabetes alliance, our respiratory portfolio, emerging markets and Japan.
Be a great place to work – building a culture that is science and patient-focused, agile and high-performing, which retains and attracts great people. This includes simplifying our organisation and improving productivity while creating a vibrant, collaborative work environment.
We believe our business strategy positions us well to manage the unprecedented challenges of a changing world and deliver sustained business success that benefits patients, stakeholders, shareholders and society.
Three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation) and the technology transfer offices of three world-leading universities (Imperial College London, University of Cambridge and UCL) have joined forces with a combined £40 million to create the Apollo Therapeutics Fund.
AstraZeneca and its global biologics R&D arm, MedImmune, have built a collaborative alliance with the University of Cambridge.
Respiratory scientists for University of Southampton and AstraZeneca have agreed a multiyear collaboration, to investigate differences in gene expression.
Apollo Therapeutics Fund aims to improve the speed and potential of university research being translated into novel medicines.
Connecting like-minded individuals from across industry and academia is helping to meet the needs of patients around the world.
AstraZeneca’s partnership with the Broad Institute at Harvard and MIT is an example of how universities and business can work together to increase the scale of research.